Mucosis brings in $4M for development of first RSV vaccine
Dutch biotech company, Mucosis, announced on Wednesday that it secured a $4 million fund awarded from the Wellcome Trust foundation. This will go toward clinical trials – a phase I dose-finding and safety study, followed by a novel phase II challenge study to assess the efficacy for its respiratory syncytial virus (RSV) intranasal vaccine called SynGEM. […]